What is the expected timeline for the full launch of the integrated platform? 
ng early. And that's been really exciting. So we're really excited about multiple avenues in generating growth in 2022.
Josh Jennings -- Cowen -- Analyst
Great. And then one last later on pipeline, captured coming on board. Any way you can detail when that -- I guess the full launch of the integrated platform could occur? NTAP is kicking in here, or just did. Then any other software or next-generation platform updates and just in terms of timelines, we should think that could catalyze -- new technology actually could catalyze stronger adoption utilization trends. Thanks again.
Todd Fruchterman -- President and Chief Executive Officer
Sure, Josh. Thanks. We're -- like I said earlier on the call, we're on track for the launch with Caption in the winter. This year, we're excited about bringing it into the market. And we're really excited about bringing into the market, because I think it's really just -- example 5 where we've been talking about which is taking the burden onto the device and away from the user and really getting it less about doing procedures and ultrasound and more about information and decision-making.
And we think Caption really helps us demonstrate that and allows people to think about that information and influencing care decisions earlier and differently than they have in the past, because this information available that wasn't readily available broadly across that clinical situation. And so we're excited about that. You'll see that in the winter coming out here.
And then as it relates to just our development pipeline, we're really excited about and I spoke about this in the call. The great progress that our technical teams have been making. We've Andrei has come in, the technical teams are realigned and I think we're making a lot of progress on our software. We're getting very close to our customer needs and being very customer-centric.
And I think you'll see the normal cadence of us with software releases coming out in a timely fashion here in the near future. And then hardware releases, like we've said, in that couple year timeframe as we look at where our evolution of our technology continues to open up the differentiation and enable value creation across the continuum was getting ultrasound technology. So you were really excited about how our technical organization is performing.
And I think we're bringing it all together, Josh, with that behavioral change with ease-of-use and we're starting that journey as the technical pieces are taking -- helping the device take more of the burden, we're really leaning into our clinical organization and generating data and our clinical education, helping users incorporate this technology and information into their clinical practices. And that's really where our lean for 2022 is to help accelerate our growth.
Josh Jennings -- Cowen -- Analyst
Excellent. Thanks so much.
Operator
[Operator Closing Remarks]
Duration: 53 minutes
Call participants:
Agnes Lee -- Investor Relations
Todd Fruchterman -- President and Chief Executive Officer
Stephanie Fielding -- Chief Financial Officer
Matt Taylor -- UBS -- Analyst
Josh Jennings -- Cowen -- Analyst
More BFLY analysis
All earnings call transcripts





ng early. And that's been really exciting. So we're really excited about multiple avenues in generating growth in 2022.
Josh Jennings -- Cowen -- Analyst
Great. And then one last later on pipeline, captured coming on board. Any way you can detail when that -- I guess the full launch of the integrated platform could occur? NTAP is kicking in here, or just did. Then any other software or next-generation platform updates and just in terms of timelines, we should think that could catalyze -- new technology actually could catalyze stronger adoption utilization trends. Thanks again.
Todd Fruchterman -- President and Chief Executive Officer
Sure, Josh. Thanks. We're -- like I said earlier on the call, we're on track for the launch with Caption in the winter. This year, we're excited about bringing it into the market. And we're really excited about bringing into the market, because I think it's really just -- example 5 where we've been talking about which is taking the burden onto the device and away from the user and really getting it less about doing procedures and ultrasound and more about information and decision-making.
And we think Caption really helps us demonstrate that and allows people to think about that information and influencing care decisions earlier and differently than they have in the past, because this information available that wasn't readily available broadly across that clinical situation. And so we're excited about that. You'll see that in the winter coming out here.
And then as it relates to just our development pipeline, we're really excited about and I spoke about this in the call. The great progress that our technical teams have been making. We've Andrei has come in, the technical teams are realigned and I think we're making a lot of progress on our software. We're getting very close to our customer needs and being very customer-centric.
And I think you'll see the normal cadence of us with software releases coming out in a timely fashion here in the near future. And then hardware releases, like we've said, in that couple year timeframe as we look at where our evolution of our technology continues to open up the differentiation and enable value creation across the continuum was getting ultrasound technology. So you were really excited about how our technical organization is performing.
 And I think we're bringing it all together, Josh, with that behavioral change with ease-of-use and we're starting that journey as the technical pieces are taking -- helping the device take more of the burden, we're really leaning into our clinical organization and generating data and our clinical education, helping users incorporate this technology and information into their clinical practices. And that's really where our lean for 2022 is to help accelerate our growth.
Josh Jennings -- Cowen -- Analyst
Excellent. Thanks so much.
Operator
[Operator Closing Remarks]
Duration: 53 minutes
Call participants:
Agnes Lee -- Investor Relations
Todd Fruchterman -- President and Chief Executive Officer
Stephanie Fielding -- Chief Financial Officer
Matt Taylor -- UBS -- Analyst
Josh Jennings -- Cowen -- Analyst
More BFLY analysis
All earnings call transcripts




